Achillion Pharmaceuticals


Discover our latest news

March 08, 2018:
Achillion to Present at the Barclays Global Healthcare Conference

February 28, 2018:
Achillion Raises Awareness for C3 Glomerulopathy With Launch of WeC3G™ Initiative as Part of Rare Disease Day 2018

February 26, 2018:
Achillion Announces ACH-4471 Receives Positive Opinion for Orphan Drug Designation in the European Union for the Treatment of C3 Glomerulopathy



Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, provided the opening remarks at the first Complement Symposium, hosted by Achillion, which was held in Orlando, Florida during the American Society of Hematology 2015 Annual Meeting,
December 6, 2015.

Dr. Peter Densen, M.D., Professor of Internal Medicine – Infectious Disease, University of Iowa, provided a detailed look at the role of thecomplement system and the relative risks of infection associated with immune modulation.

Dr. Scott Barnum, Ph.D., Department of Microbiology at the University of Alabama at Birmingham, presented a review of complement immune-biology and the roles of the classical, lectin, and alternative pathways.

Dr. David Apelian, M.D., Ph.D., Chief Medical Officer of Achillion Pharmaceuticals, discussing the nomination of ACH-4471, small-molecule complement factor D inhibitor, being developed for the treatment of ultra-rare diseases,
including PNH.